Allakos Inc

NASDAQ ALLK

Download Data

Allakos Inc Days Payable Outstanding (DPO) 1 year YoY Change (%) for the quarter ending March 31, 2024: 222.51%

Allakos Inc Days Payable Outstanding (DPO) 1 year YoY Change (%) is 222.51% for the quarter ending March 31, 2024. The days payables outstanding ratio measures the average number of days it takes for a company to pay its suppliers. It is calculated by dividing accounts payable by the cost of revenue and then multiplying by 365. This ratio indicates the average payment period for suppliers and reflects the efficiency of managing trade payables. A longer period suggests extended payment terms and potential working capital advantages. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Allakos Inc Days Payable Outstanding (DPO) for the quarter ending March 31, 2023 was 1,662.60.
NASDAQ: ALLK

Allakos Inc

CEO Dr. Robert Alexander Ph.D.
IPO Date July 19, 2018
Location United States
Headquarters 975 Island Drive, Redwood City, CA, United States, 94065
Employees 131
Sector Healthcare
Industry Biotechnology
Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

CRBU

Caribou Biosciences Inc

NA

NA

KURA

Kura Oncology Inc

NA

NA

NXTC

NextCure  Inc

NA

NA

GTHX

G1 Therapeutics Inc

NA

NA

HRTX

Heron Therapeuti

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email